Chewable ADHD Medication
Methylphenidate Hydrochloride (HCl) Chewable Tablets
A flexible alternative for ADHD therapy.
AB-rated to Methylin®*
Short-acting, immediate-release chewable tablet
Suitable for a broad range of patients-both children and adults1,2
Extensively supported by free patient educational resources developed by Lupin Pharmaceuticals, Inc.
Grape flavored, precise dosing formulation3
Generic pricing - no savings card needed
Tablets not shown at actual size.
*Methylin® is a registered trademark of Mallinckrodt LLC.
Not recommended for children under 6 years of age.4
Dosage and Administration†
Methylphenidate HCl Chewable Tablets are part of a total treatment program for ADHD that may include counseling or other therapies.9
Children (> 6 years)4
Dosage should be individualized according to the needs and responses of the patient.
Initiate in small doses, with gradual weekly increments.
Daily dosage above 60 mg is not recommended.
Start with 5 mg twice daily (before breakfast and lunch) with gradual increments of 5 to 10 mg weekly.
Administer in divided doses 2 or 3 times daily, preferably 30 to 45 min before meals
Average dosage is 20 to 30 mg daily.
Some patients may require 40 to 60 mg daily. In others, 10 to 15 mg daily will be adequate.
Patients who are unable to sleep if medication is taken late in the day should take the last dose before 6 p.m.
Directions - This product should be taken with at least 8 ounces (a full glass) of water or other fluid.
† See Prescribing Information for full Dosing and Administration instructions.
Provide your patients with useful information.
We are committed to working with you to help your patients navigate a new ADHD diagnosis. To help your patients get started, we've developed a fact-based and easy-to-read guide. It discusses diagnosis, available treatments, lifestyle tips for raising a child with ADHD, support strategies, school tips and more.
Download a free PDF copy of Growing Up With ADHD now or complete the form to obtain print booklets for your patients.
"ADHD: Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention- Deficit/Hyperactivity Disorder in Children and Adolescents." Pediatrics (2011), vol. 128, no. 5.
"European consensus statement on diagnosis and treatment of adult ADHD: The European Network Adult ADHD" Kooij S., Bejerot S., Blackwell A., Caci H., et al. BMC Psychiatry (2010), vol 10, no. 67.
Committee for Medicinal Products for Human Use (CHMP), European Medicines Agency. Reflection Paper: Formulations of Choice for the Paediatric Population (EMEA/CHMP/PEG/194810/2005).
Methylphenidate Hydrochloride Chewable Tablets [package insert]. Somerset, NJ: GAVIS Pharmaceuticals, LLC.; 2015.
"A Review of Pharmacological Management of Attention-Deficit/Hyperactivity Disorder." Briars L. and Todd T. The Journal of Pediatric Pharmacology and Therapeutics (2016) vol. 21, no. 3.
"ADHD Parents Medication Guide." American Academy of Child & Adolescent Psychiatry and American Psychiatric Association (2013).
"ADHD: Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention- Deficit/Hyperactivity Disorder in Children and Adolescents." Pediatrics (2015), vol. 128 (Supplement).
"Safety of Chewable Tablets for Children." Michele Th., Knorr B., Vada E., Reiss Th. Journal of Asthma (2002), vol. 39, No. 5, p: 391-403.
"Clinical Practice: Adult Attention Deficit-Hyperactivity Disorder." Volkow, ND, Swanson, JM. The New England Journal of Medicine (2013), vol. 369, no. 20.
ATTENTION DEFICIT DISORDERS, NARCOLEPSY
Methylphenidate Hydrochloride Chewable Tablets are indicated as an integral part of a total treatment program which typically includes other remedial measures (psychological, educational, social) for a stabilizing effect in children with a behavioral syndrome characterized by the following group of developmentally inappropriate symptoms: moderate-to-severe distractibility, short attention span, hyperactivity, emotional lability, and impulsivity.
Important Safety Information
- Children less than 6 years of age - Methylphenidate Hydrochloride Chewable Tablets should not be used in children under six years, since safety and efficacy in this age group have not been established.
- Monoamine Oxidase Inhibitors - Methylphenidate Hydrochloride Chewable Tablets are contraindicated during treatment with monoamine oxidase inhibitors, and also within a minimum of 14 days following discontinuation of a monoamine oxidase inhibitor (hypertensive crises may result).
- Anxiety, Tension, and Agitation - Marked anxiety, tension, and agitation are contraindications to Methylphenidate Hydrochloride Chewable Tablets, since the drug may aggravate these symptoms.
- Hypersensitivity - Methylphenidate Hydrochloride Chewable Tablets are also contraindicated in patients known to be hypersensitive to the drug, in patients with glaucoma, and in patients with motor tics or with a family history or diagnosis of Tourette's syndrome.
- Sudden Death and Pre-Existing Structural Cardiac Abnormalities or Other Serious Heart Problems
Stimulant products generally should not be used in children, adolescents, or adults with known serious structural cardiac abnormalities, cardiomyopathy, serious heart rhythm abnormalities, or other serious cardiac problems. Stroke, and myocardial infarction have been reported in adults taking stimulant drugs.
- Hypertension and other Cardiovascular Conditions
Stimulant medications can cause modest changes in blood pressure and heart rate. Use caution when treating patients whose underlying medical conditions might be compromised by increases in blood pressure or heart rate (e.g., those with pre-existing hypertension, heart failure, recent myocardial infarction, or ventricular arrhythmia).
- Peripheral Vasculopathy, Including Raynaud's Phenomenon - Stimulants, including Methylphenidate Hydrochloride Chewable Tablets, are associated with peripheral vasculopathy, including Raynaud's phenomenon. Signs and symptoms are usually intermittent and mild; however, very rare sequelae include digital ulceration and/or soft tissue breakdown.
- Pre-Existing Psychosis - Administration of stimulants may exacerbate symptoms of behavior disturbance and thought disorder in patients with a pre-existing psychotic disorder.
- Bipolar Illness - Particular care should be taken in using stimulants to treat ADHD in patients with comorbid bipolar disorder because of concern for possible induction of a mixed/manic episode in such patients.
- Emergence of New Psychotic or Manic Symptoms - Treatment emergent psychotic or manic symptoms, e.g., hallucinations, delusional thinking, or mania in children and adolescents without a prior history of psychotic illness or mania can be caused by stimulants at usual doses.
- Aggression - Aggressive behavior or hostility is often observed in children and adolescents with ADHD. Patients beginning treatment for ADHD should be monitored for the appearance of or worsening of aggressive behavior or hostility.
- Seizures - There is some clinical evidence that stimulants may lower the convulsive threshold in patients with prior history of seizures, in patients with prior EEG abnormalities in absence of seizures, and, very rarely, in patients without a history of seizures and no prior EEG evidence of seizures. In the presence of seizures, the drug should be discontinued.
- Priapism - Prolonged and painful erections, sometimes requiring surgical intervention, have been reported with methylphenidate products in both pediatric and adult patients.
- Long-Term Suppression of Growth - Growth should be monitored during treatment with stimulants, and patients who are not growing or gaining height or weight as expected may need to have their treatment interrupted.
- Difficulties with accommodation and blurring of vision have been reported with stimulant treatment.
- Nervousness and insomnia are the most common adverse reactions but are usually controlled by reducing dosage and omitting the drug in the afternoon or evening.
- Other reactions include hypersensitivity (including skin rash, urticaria, fever, arthralgia, exfoliative dermatitis, erythema multiforme with histopathological findings of necrotizing vasculitis, and thrombocytopenic purpura); anorexia; nausea; dizziness; palpitations; headache; dyskinesia; drowsiness; blood pressure and pulse changes, tachycardia; angina; cardiac arrhythmia; abdominal pain; weight loss during prolonged therapy; libido changes; and rhabdomyolysis.
WARNINGS AND PRECAUTIONS